LISATA THERAPEUTICS, INC. — Form 8-K/A
Filed November 19, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 78/100
What the filing says
On September 17, 2026, Lisata Therapeutics acquired Marea Therapeutics for approximately $377.8M in consideration consisting of 1,793,129 common shares (~19.9% of pre-merger outstanding) and 211,365 Series C Preferred shares (convertible 1:1000 to common). Concurrently, a $225M PIPE closed on September 18, 2026 via 150,868 Series C Preferred shares at $1,491.37/share. Post-conversion (pending stockholder approval), Marea shareholders hold ~59.5%, PIPE investors ~38.1%, and legacy Lisata shareholders ~2.4% of fully diluted shares.
Why this rating
Transformational for $23.6M-market-cap company: $377.8M acquisition + $225M cash raises ~$602.8M total value—25.5x company's current market cap. Adds meaningful R&D pipeline (IPR&D valued ~$292.9M) but massive dilution and cash burn risk. Material near-term upside IF pipeline succeeds; substantial downside if clinical programs fail.
Tradability signal
NO TRADE
No trade: positive news with only -3.9% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.33% over 4 hrs, n=592). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.92 ▲ 4.03% | at our read · unknown $0.88 | +10 min · unknown $0.88 ▲ 0.00% | +30 min · unknown $0.90 ▲ 1.93% | +1 hr · unknown $0.90 ▲ 1.93% | +4 hrs · unknown $0.88 ▼ 0.34% |
The stock had already moved -3.88% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.